USPTO Declines to Institute All Inter Partes Review Petitions Filed by CFAD of Insys U.S. Patents Directed to SUBSYS (fentanyl sublingual spray)

PHOENIX, March 10, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) declined to institute an inter partes review of U.S. Patent Nos. 8,486,972, 8,835,459 and 8,835,460, which cover the fentanyl formulation of SUBSYS® (fentanyl sublingual spray).

“SUBSYS is the first and only sublingual spray available for breakthrough cancer pain. This dismissal is indicative of the pioneering efforts by Insys to bring innovative therapies to patients to manage their underlying constant cancer pain,” said Dr. John N. Kapoor, Chairman, President and Chief Executive Officer of Insys. “As a Company, we remain committed to the defense and vigorous enforcement of our intellectual property estate with the goal of creating long-term shareholder value.”

In addition to the four U.S. patents granted by the United States Patent and Trademark Office, Insys was recently granted one additional U.S. Patent 9,241,935 covering the SUBSYS formulation, further strengthening the SUBSYS patent estate.

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys seeks to address the clinical shortcomings of existing commercial products. Insys currently markets one product: SUBSYS® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

SUBSYS® and SYNDROS™ are trademarks of Insys Therapeutics, Inc.

Investor Contact: Lisa M. Wilson, President In-Site Communications, Inc. Phone: 212-452-2793 Email:

Source:Insys Therapeutics, Inc.